Cue biopharma reports second quarter 2024 financial results and recent business highlights

Boston, aug. 19, 2024 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific t cells, provided a business and financial update for the second quarter 2024.
CUE Ratings Summary
CUE Quant Ranking